




Transcell Oncologics's cell-based platforms portfolio Transtoxbio inks an agreement with OncoSeek Bio Pvt. Ltd (OSB), a Hyderabad based boutique Contract Research Organization.

As part of this engagement OSB sources various cells and cellular platforms from Transtoxbio portfolio to enable it's in-house exploratory R&D, discovery and screening on novel platforms that use various monolayers or 3D structures including spheroids/organoids/microfluidics and other printed technologies. OSB also plans to use Transtoxbio's new league of human sourced primary mature cells and primary stem cells (CD34+ cells - TRANS-HSC) in generating new relevant animal models for several disease conditions that have no true preclinical animal model representation currently for pharmaceutical research. OSB is keen to treat Transtoxbio portfolio as it's main cell-based platforms or free suspended cells supplier for all it's preclinical models and services to be offered to global industry and for its own discovery programs.



About www.transtoxbio.com portfolio:

All human biological discards sourced primary progenitor adult stem cells based platforms that can predict species relevant test end points. Additionally, some of these platforms have capabilities to humanize either animals or biomaterials, transdifferentiate to organ specific cells like human hepatocytes, cardiocytes, beta cells, bone, cartilage with documented applications/use cases in preclinics addressing pharmaceuticals, cosmeceutical industry need.

About OncoSeek Bio:

Offers preclinical pathology services, Advanced animal and patient derived xenograft models for drug discovery, Invitro testings for personalized cancer care.

For Transtoxbio:

Transcell Oncologics

Technology Business Incubator

Hyderabad Central University

+91 7799914445

enquiry@transtoxbio.com

For OncoSeek Bio:

ASPIRE - BioNEST

bharadwaj@oncoseekbio.com

91-9100851758